If you searched for hydrogen water and altitude sickness expecting a story about a promising new antioxidant, the most recent trial does not tell that story. It reported that hydrogen-rich water did not reduce oxidative stress damage in people with chronic mountain sickness, that a marker of oxidative damage went up rather than down relative to placebo, and that the researchers’ own conclusion warns it may increase oxidative risk in people with a higher body mass index[1].
That is an unusual result in this field and it is worth walking through carefully, because it is also the best-designed altitude trial that exists.
What chronic mountain sickness is
Chronic mountain sickness is what happens when someone living permanently at high altitude fails to adapt to it. The body over-produces red blood cells in response to low oxygen, the blood thickens, and the result is headaches, dizziness, fatigue, breathlessness and sleep disturbance that persists as long as the person stays at altitude. It is diagnosed using a scoring system known as the Qinghai score[1].
It is not the same thing as acute mountain sickness, which is what a tourist gets in the first days after flying into a high-altitude city. Chronic mountain sickness affects long-term residents of high-altitude regions, and it is a genuine public health problem in the Andes and on the Tibetan plateau.
Oxidative stress is implicated in how it develops, which is the entire reason anyone thought to test an antioxidant against it[1].
Why hydrogen was a reasonable thing to try
Molecular hydrogen reacts selectively with hydroxyl radical, the most destructive reactive oxygen species, while largely sparing the radicals the body uses for signalling[2]. That selectivity is what distinguished it from conventional antioxidants and drove two decades of research across a long list of conditions[3].
Hypoxia-driven oxidative stress in a defined patient population, with an established diagnostic score and a measurable set of biomarkers, is on paper a sensible target. Hydrogen-rich water is also cheap, easy to blind with plain water, and has an unremarkable safety record, which makes it practical to trial.
The 2026 randomized trial
The main evidence is an 8-week randomized, blinded, placebo-controlled trial conducted at the Tibetan Hospital of Nagqu in China, registered in advance as ChiCTR2400082685[1].
Adults with untreated chronic mountain sickness, defined by Qinghai score, were randomly assigned in a one-to-one ratio to receive 990 millilitres per day of hydrogen-rich water or placebo, using a dynamic minimisation method. Participants, clinicians and investigators were all blinded to allocation[1].
The pre-specified primary endpoint was the change in oxidative stress biomarkers from baseline to week 8. The panel was broad: catalase, glutathione, malondialdehyde, superoxide dismutase, 8-hydroxy-2-deoxyguanosine and total antioxidant capacity[1].
Between July and December 2024, 60 participants were randomized. One person in the placebo group did not receive treatment and was excluded, leaving 59 in the analysis[1].
What it found
Two of the six biomarkers changed significantly more in the hydrogen group than in placebo. Malondialdehyde changed by plus 2.11, with a 95 percent confidence interval of 1.13 to 3.09 and p less than 0.001. Total antioxidant capacity changed by plus 2.86, with a 95 percent confidence interval of 0.09 to 5.64 and p equal to 0.043[1].
The direction of the first one is the problem. Malondialdehyde is a product of lipid peroxidation, which means it is a marker of oxidative damage that has already happened. Higher is worse. An antioxidant that works should push it down.
Total antioxidant capacity moving up is the direction you would want, so the trial produced one result pointing each way. The authors described this plainly, concluding that hydrogen-rich water demonstrated both pro-oxidative and antioxidative effects[1].
The subgroup finding sharpens it. In participants with a body mass index of 24 or above, the increase in malondialdehyde was more pronounced, at a change of plus 2.57, with p equal to 0.02 for interaction[1].
Their overall conclusion is worth quoting rather than paraphrasing: hydrogen-rich water did not reduce oxidative stress-induced damage and may increase oxidative risk in individuals with higher body mass index[1].
The side effect numbers
Adverse events occurred in 50 percent of the hydrogen group, 15 of 30 people, and in 37 percent of the placebo group, 11 of 29. Dizziness was the most common[1].
The trial did not report that difference as statistically significant, and with 59 people it would take a large gap to reach significance, so this is not evidence that hydrogen water causes side effects. It is worth stating because hydrogen water is routinely described as having essentially no adverse effects, and here the hydrogen arm reported more of them than the placebo arm did.
Dizziness being the most common event in a study of people with chronic mountain sickness is also difficult to interpret, since dizziness is a symptom of the condition itself.
The companion study
A second study, published in 2025 with an overlapping author group, tested hydrogen-rich water in chronic high-altitude disease over 60 days[4].
50 participants were recruited and assigned to hydrogen-rich water or placebo water. Seven were lost to follow-up, leaving 43 who completed, 23 on hydrogen and 20 on placebo. Baseline characteristics did not differ significantly between groups[4].
The transcriptomic analysis is the interesting part. Differentially expressed genes in the placebo group between pre- and post-intervention were predominantly associated with inflammation and cytokine pathways, whereas hydrogen treatment significantly downregulated those pathways. Network analysis identified six hub genes, including tumour necrosis factor, interleukin-1 beta, and several C-C motif chemokine ligands[4].
But the direct measurements did not follow. Oxidative stress and inflammatory markers showed a non-significant downward trend after 60 days of hydrogen-rich water[4]. Non-significant is the operative word, and the authors reported it as such.
So the second study found gene expression changes without confirmatory biomarker changes, and the first found a biomarker change in the wrong direction. Those are not contradictory so much as jointly unconvincing.
Three things that limit both studies
They are not independent. Several authors appear on both papers and both were conducted through the same Chinese hospital network. Two studies from overlapping groups are one line of evidence, not a replication.
Neither one made symptoms the primary endpoint. The 2026 trial’s pre-specified primary endpoint was the change in oxidative stress biomarkers[1]. Nobody has tested whether hydrogen water makes a person with chronic mountain sickness feel better, sleep better, or score lower on the Qinghai scale as a primary outcome. That is the question a patient would ask, and it has not been answered.
They are small. Fifty-nine and forty-three analysed participants respectively. At that size, a single unusual subgroup can move a biomarker average, and the subgroup finding in people with higher body mass index rests on a fraction of 30 people.
What about ordinary altitude sickness
The obvious practical question, from anyone about to travel to a high-altitude destination, is whether hydrogen water helps with the headache and nausea of arriving somewhere high.
There is no trial answering that. Both studies above enrolled people with an established chronic condition from living at altitude long-term, not travellers experiencing acute mountain sickness. The physiology is different, the time course is different, and results in one do not transfer to the other.
The established measures for acute altitude illness, ascending gradually, allowing time to acclimatise, and descending if symptoms worsen, are not things a supplement substitutes for. Severe forms of acute altitude illness can be life-threatening and are a medical emergency, so treating any altitude symptom as something to manage with a bottle of water is a bad idea regardless of what is dissolved in it.
The bottom line
The best trial on hydrogen water at altitude is an 8-week randomized, blinded, placebo-controlled study in 59 people with chronic mountain sickness. It concluded that hydrogen-rich water did not reduce oxidative stress damage, showed both pro-oxidative and antioxidative effects, and may increase oxidative risk in people with a body mass index of 24 or above[1].
A companion 60-day study found favourable gene expression changes but only a non-significant downward trend in the actual oxidative stress and inflammation markers[4].
Neither study measured whether anyone felt better. Neither tested travellers with acute altitude sickness. And the negative result comes from the more rigorous of the two designs.
On the evidence that exists today, there is no case for buying hydrogen water for altitude, and one published warning worth noting if your body mass index is 24 or higher.
References
- Does Hydrogen-Rich Water Reduce Oxidative Stress in Patients with Chronic Mountain Sickness? A Randomized, Blinded, Controlled Trial. High Altitude Medicine and Biology, 2026
- Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nature Medicine, 2007
- Molecular hydrogen as an emerging therapeutic medical gas for neurodegenerative and other diseases. Oxidative Medicine and Cellular Longevity, 2012
- Hydrogen-rich water supplementation attenuates oxidative stress and inflammation in chronic high-altitude disease patients: A double-blind randomized placebo-controlled study. Food Research International, 2025
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
